Study guide

12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration

AACN Cardiac Medicine Certification CMC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview and the CMC Test Plan

1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them

2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease

2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy

3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease

3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup

4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions

4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation

5 Chapter 5: Vascular Conditions and Vascular Interventions

5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications

6 Chapter 6: Shock States and Mechanical Circulatory Support

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD

7 Chapter 7: Cardiac Procedures and Structural Heart Interventions

7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

8 Chapter 8: Cardiovascular Pharmacology

8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure

9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary

9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients

10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral

10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

11 Chapter 11: Monitoring and Diagnostics

11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography

12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions

12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease

12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration

Key Takeaways Explain This Topic AI

Urgent indications for renal replacement therapy follow AEIOU: refractory acidosis, electrolyte derangement (especially hyperkalemia above about 6.5 mEq/L or with ECG changes), intoxications, volume overload unresponsive to diuretics, and uremia with pericarditis, encephalopathy or bleeding.

STARRT-AKI and AKIKI showed no survival benefit to routinely starting renal replacement therapy early in the absence of an urgent indication, and accelerated initiation left more patients dialysis-dependent at 90 days.

The standard continuous renal replacement therapy dose is a delivered effluent of 20-25 mL/kg/h, usually prescribed at 25-30 mL/kg/h to allow for downtime; higher doses have not improved survival.

Regional citrate anticoagulation is the KDIGO-preferred first-line circuit anticoagulant: target post-filter ionized calcium 0.25-0.35 mmol/L and systemic ionized calcium 1.0-1.2 mmol/L, and treat a total calcium to ionized calcium ratio above 2.5 with worsening metabolic acidosis as citrate accumulation.

Continuous therapy is preferred in the hemodynamically unstable cardiac patient because slow, continuous fluid removal avoids the intradialytic hypotension and myocardial stunning caused by rapid intermittent hemodialysis; net ultrafiltration rates above about 1.75 mL/kg/h are associated with worse outcomes.

Last updated: August 2026

When to Start: AEIOU and the Timing Evidence

Acute kidney injury (AKI) complicates a third or more of cardiogenic shock, decompensated heart failure and post-arrest admissions, and cardiorenal interaction is bidirectional - low forward flow and high central venous pressure both injure the kidney, and the failing kidney worsens congestion, acidosis, and arrhythmia risk.

The urgent indications are remembered as AEIOU :

Letter Indication Findings that make it urgent

A Acidosis Metabolic acidosis with pH below about 7.1-7.15 refractory to bicarbonate, especially when bicarbonate loading is limited by volume overload or hypernatremia

E Electrolytes Hyperkalemia above about 6.5 mEq/L, or any level with ECG changes (peaked T waves, widened QRS, sine wave), refractory to medical therapy; also severe hypercalcemia or tumor lysis

I Intoxications Dialyzable toxins - salicylates, lithium, toxic alcohols (methanol, ethylene glycol), metformin-associated lactic acidosis, theophylline, valproate

O Overload Pulmonary edema and hypoxemia unresponsive to escalating loop diuretics, particularly when it prevents delivery of nutrition, blood products, or antibiotics

U Uremia Uremic pericarditis (a pericardial friction rub - a hard indication and a tamponade risk), uremic encephalopathy or asterixis, uremic bleeding from platelet dysfunction

Timing in the absence of an urgent indication has been settled by trial data. ELAIN favored early initiation but was single-center; AKIKI and IDEAL-ICU found no benefit; STARRT-AKI (2020) randomized more than 3,000 patients to accelerated versus standard initiation and found no difference in 90-day mortality, with more dialysis dependence at 90 days in the accelerated arm . Current practice is therefore to start for a clear indication or persistent, non-recovering severe AKI, not by creatinine number alone. The CMC-relevant version: a rising creatinine with adequate urine output and no AEIOU criterion is not by itself an indication to cannulate a shocked cardiac patient.

The Four Transport Principles

Diffusion - solute moves down a concentration gradient across the membrane into countercurrent dialysate. Efficient for small molecules: potassium, urea, creatinine. This is what makes a therapy a "D" therapy (HD, CVVHD).

Convection - solvent drag: a pressure gradient pushes plasma water across the membrane and solutes are carried with it. Clears middle molecules better than diffusion. This is the "H" in CVVH and requires replacement fluid.

Ultrafiltration - the pressure-driven removal of plasma water itself. This is how volume comes off, and it is the only thing SCUF does.

Adsorption - solute binding to the membrane surface. Contributes to cytokine and some drug removal and to progressive loss of filter performance over time.

Modality Principle Duration Fluid removal Best fit

Intermittent hemodialysis (IHD) Diffusion (plus UF) 3-4 h, 3-6 times/week Rapid, often 1-4 L per session Hemodynamically stable patient, severe hyperkalemia needing fast correction, dialyzable intoxication

  • CVVH Convection Continuous Titratable, gradual Middle-molecule clearance, unstable patient
  • CVVHD Diffusion Continuous Titratable, gradual Small-solute clearance, unstable patient
  • CVVHDF Both Continuous Titratable, gradual Most common ICU continuous prescription

SCUF Ultrafiltration only Continuous Pure volume removal, typically 100-300 mL/h Diuretic-resistant volume overload without a clearance problem

SLED / PIRRT Diffusion at lower flows 6-12 h daily Gradual within the session Middle ground - hemodynamic tolerance with daytime staffing

Isolated venovenous ultrafiltration Ultrafiltration only Hours to days Set rate, commonly 100-500 mL/h Diuretic-refractory acute decompensated heart failure

Why Continuous Therapy in the Unstable Cardiac Patient

Intermittent hemodialysis removes fluid over 3-4 hours. A patient with a fixed or barely responsive stroke volume - severe systolic dysfunction, aortic stenosis, restrictive physiology, right ventricular failure, or an LVAD with limited preload reserve - cannot increase cardiac output to compensate for a rapid drop in plasma volume, and plasma refill from the interstitium is too slow. The result is intradialytic hypotension , which occurs in up to a quarter of sessions and is not merely a nuisance: repeated intradialytic hypotension causes myocardial stunning , with new regional wall-motion abnormalities that appear during the session, resolve over hours, and over time contribute to progressive myocardial fibrosis and worse survival. Continuous therapy removes the same volume over 24 hours at a fraction of the hourly rate, preserving the ability of interstitial fluid to refill the vascular space. That hemodynamic tolerance - not superior survival, which trials have not demonstrated - is the reason continuous modalities dominate in cardiogenic shock and post-arrest care.